There are constantly new funds on the market, the increase in the number of funds for investors to provide a wide range of choices, the advantage of the new funds is that the subscription fee is low, recently Tianhong Fund released a new fund, which is Tianhong Pharmaceuticals Innovative Fund, so how is this fund?
How about Tianhong Medical Innovation Fund?
1Risk-return characteristics: This fund is a hybrid fund, its risk-return expectations are higher than money market funds and bond funds, lower than equity funds. This fund will invest in the underlying stocks of the Hong Kong Stock Connect, and will be exposed to risks specific to the Hong Kong Stock Connect mechanism due to differences in the investment environment, investment targets, market systems and trading rules.
2 investment strategy: the fund mainly layout of Shanghai and Shenzhen and Hong Kong stocks in the pharmaceutical industry in the high degree of prosperity in the direction of innovation, through in-depth research to take a bottom-up investment approach, selected high-growth pharmaceutical innovation direction of the underlying, the innovation direction of the pharmaceutical industry, specifically including innovative drugs (chemical drugs, biological drugs, vaccines), innovative devices, and innovative services industry chain (CRO, CDMO). Innovative pharmaceutical companies involved in the field of industry, including the chemical pharmaceutical industry, traditional Chinese medicine industry, biologics industry, pharmaceutical business industry, medical device industry, medical services industry.
3 Fund Manager: Mr. Guo Xiangbo: Master's degree from New York University, served as department head of Beijing Tongrentang Science and Technology Development Company Limited, joined Tianhong Fund Management Co. He was the fund manager of Tianhong Bond Initiated Securities Investment Fund.